Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

157.14 -0.84 (-0.53%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,599,713
Open 155.08
Bid (Size) 155.21 (1)
Ask (Size) 159.06 (1)
Prev. Close 157.98
Today's Range 154.35 - 157.60
52wk Range 95.02 - 172.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors. 
Via The Motley Fool

Performance

YTD
+14.73%
+14.73%
1 Month
-6.34%
-6.34%
3 Month
+8.45%
+8.45%
6 Month
+23.83%
+23.83%
1 Year
+39.49%
+39.49%

More News

Read More
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
Via The Motley Fool
This Could Be Novo Nordisk's Next Big Weight-Loss Product
Via The Motley Fool
The Best Stocks to Invest $5,000 in Right Now
Via The Motley Fool
Better Dividend Stock: Eli Lilly or Novo Nordisk?
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Why Novo Nordisk Stock Is Falling Today
Via The Motley Fool
This Pharma's Sales Are So Hot It's Trying to Curb Demand
Via The Motley Fool
InvestorNewsBreaks – Novo Nordisk (NYSE: NVO) Featured in Analysis Report
Via Investor Brand Network
Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
Via Investor's Business Daily
7 Top Stock Tips for June 2023
Via InvestorPlace
3 Biotech Stocks With Blockbuster Potential
Via InvestorPlace
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
Via Investor's Business Daily
Novo Nordisk's Oral Weight-Loss Drug Shows Significant Benefit
Via Benzinga
Tesla, Zoom, Hepion, Pfizer, ZIM: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
Why Pfizer Stock Crushed the Market on Monday
Via The Motley Fool
S&P 500: Tesla Among Stock Winners Monday; Nike, Micron Slide
Via Investor's Business Daily
Pfizer Stock Pops: Study Shows Company's Oral Weight Loss Drug Could Be As Effective As Novo Nordic's Ozempic Injection
Via Benzinga
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Via Investor's Business Daily
EU Slaps Meta With Penalty For Data Privacy Violation, Uber's Diversity Leader Faces Heat, China Bans Some Of Micron's Product Sales: Today's Top Stories
Via Benzinga
Mayo Clinic Study Highlights Potential of Novo Nordisk's Wegovy for Cardiac Health and Weight Loss
Via Benzinga
If You Invested $10,000 in Novo Nordisk in 2020, This Is How Much You Would Have Today
Via The Motley Fool
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Via MarketBeat
Topics Economy
Exposures Economy
Is Novo Nordisk Stock a Screaming Buy Right Now?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.